BACKGROUND: Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined. METHODS: We identified 15 cases of pathologically confirmed HSTCL in the institution's database. Clinical characteristics and treatment results were reviewed. RESULTS: Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy. Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients. Median duration of CR was 8 months (range 2 to 32+ months) with four patients currently alive and in CR at 5, 8, 12, and 32 months, respectively. Median overall survival (OS) was 11 months (range 2 to 36+ months). Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR. Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain. CONCLUSION: A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.
BACKGROUND:Hepatosplenic T-cell lymphoma (HSTCL) is a rare peripheral T-cell lymphoma; treatment with standard anthracycline-containing chemotherapy regimens has been disappointing, and an optimal treatment strategy for this patient population has not yet been determined. METHODS: We identified 15 cases of pathologically confirmed HSTCL in the institution's database. Clinical characteristics and treatment results were reviewed. RESULTS: Complete responses (CRs) were achieved in 7 of 14 patients who received chemotherapy. Achievement of CR was followed by hematopoietic stem-cell transplantation in three patients. Median duration of CR was 8 months (range 2 to 32+ months) with four patients currently alive and in CR at 5, 8, 12, and 32 months, respectively. Median overall survival (OS) was 11 months (range 2 to 36+ months). Patients who achieved a CR had a median OS of 13 months, compared with 7.5 months in patients who did not achieve a CR. Risk factors associated with worse outcome included male gender, failure to achieve a CR, history of immunocompromise, and absence of a T-cell receptor gene rearrangement in the gamma chain. CONCLUSION: A better understanding of the pathophysiology of HSTCL and new therapeutic strategies are needed.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: S Roncella; G Cutrona; M Truini; I Airoldi; A Pezzolo; A Valetto; D Di Martino; P Dadati; A De Rossi; M Ulivi; I Fontana; A Nocera; U Valente; M Ferrarini; V Pistoia Journal: Haematologica Date: 2000-03 Impact factor: 9.941
Authors: Meena Thayu; Jonathan E Markowitz; Petar Mamula; Pierre A Russo; William I Muinos; Robert N Baldassano Journal: J Pediatr Gastroenterol Nutr Date: 2005-02 Impact factor: 2.839
Authors: Rocío Hassan; Sergio A L Franco; Claudio Gustavo Stefanoff; Sergio O Romano; Hilda R Diamond; Luiz G P Franco; Héctor N Seuánez; Ilana R Zalcberg Journal: Pathol Int Date: 2006-11 Impact factor: 2.534
Authors: N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield Journal: J Clin Oncol Date: 1999-12 Impact factor: 44.544
Authors: S Coventry; H H Punnett; E Z Tomczak; D Casher; M Koehler; M J Borowitz; C A Griffin; J P de Chadarévian Journal: Pediatr Dev Pathol Date: 1999 Sep-Oct
Authors: H Wu; M A Wasik; G Przybylski; J Finan; B Haynes; H Moore; D G Leonard; K T Montone; A Naji; P C Nowell; M Kamoun; J E Tomaszewski; K E Salhany Journal: Am J Clin Pathol Date: 2000-04 Impact factor: 2.493
Authors: A Tanase; N Schmitz; H Stein; A Boumendil; H Finel; L Castagna; D Blaise; N Milpied; G Sucak; A Sureda; K Thomson; E Vandenberghe; A Vitek; P Dreger Journal: Leukemia Date: 2014-09-19 Impact factor: 11.528